In this interview, Innate Pharma’s Yannis Morel, Executive Vice President of product portfolio strategy and business development, delves into the unique advantages of using multi-specific antibodies capable of engaging NK cells against tumours for oncology indications, and shares key data from the company’s ongoing and recent clinical trials.
Credit: Innate Pharma
Yannis Morel, Executive Vice President of product portfolio strategy and business development of Innate Pharma SA, offers insight on engineering antibodies to develop antibody-based NK cell therapeutics. He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment.
Additionally, Morel shares highlights and key clinical data from Innate Pharma’s pipeline and as well as his predictions on where the sector is headed, meanwhile considering the impact of accelerating technological innovations.
As a biotech, what work does Innate Pharma do in the biopharma industry?
Innate Pharma is an international clinical-stage biotechnology oncology company based in France. We specialise in the development of new cutting-edge immunotherapies, based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Innate Pharma’s approach relies primarily on the innate immune system and aims to mobilise natural killer (NK) cells to directly kill cancer cells through therapeutic antibodies or our proprietary ANKET® (Antibody-based NK cell Engager Therapeutics) platform.
Pharmaceutical companies such as Sanofi and AstraZeneca are currently conducting several high-potential clinical development programmes in oncology in collaboration with Innate Pharma. Innate Pharma has also partnered with Takeda to develop an antibody drug conjugate (ADC).
Can you describe Innate Pharma’s clinical stage pipeline?
Innate Pharma currently has seven clinical-stage assets from Phase I to Phase III.
Our most-advanced proprietary antibody lacutamab is currently being evaluated in a multi-cohort Phase II trial, named TELLOMAK, for the treatment of advanced forms of cutaneous T-cell lymphoma (Sezary syndrome and Mycosis fungoides), and two trials (Phase Ib and Phase II) are ongoing for the treatment of peripheral T-cell lymphoma (PTCL). Final results from the TELLOMAK study are expected by the end of 2023, as well as preliminary data from the Phase Ib trial in PTCL.
The monalizumab antibody licensed to AstraZeneca for oncology is currently being evaluated in a Phase III trial called PACIFIC-9, in non-resectable early-stage non-small cell lung cancer (NSCLC).
Innate Pharma also developing IPH5201 in collaboration with AstraZeneca. IPH5201 is being investigated in a Phase II trial, MATISSE, in combination with durvalumab (anti-PD-L1) and chemotherapy, in patients with resectable early-stage NSCLC .
Additionally, Innate Pharma also has an emerging portfolio of next-generation therapeutics mostly consisting of multi-specific antibodies capable of engaging NK cells against tumours. These are capable of targeting different types of cancer. To date, we are conducting three of these programmes in collaboration with Sanofi. Two are already in Phase I and we have our first proprietary ANKET® called IPH6501 hitting the clinic at the end of this year.
Credit: Innate Pharma
What are some of the biggest advantages to using NK cell therapy to treat cancer?
The innate immune system represents the first line of defense of the organism. Firstly, it initiates the immune response and subsequently helps to activate the adaptive immunity. NK cells are an important component of the innate immunity and their biggest advantage relies on their immediate ability to recognise and eliminate cancer cells through direct killing and to produce cytokines and chemokines that shape the adaptive immune response.
In contrast to NK cells, T cells are not autonomous and need to be primed by the innate immune system before becoming anti-tumour effector cells.
With Innate Pharma’s proprietary next generation multi-specific NK cell engagers platform, multi-specific antibodies bind on one end to activating receptors expressed on NK cells (NKp46, CD16) and on the other end to a tumour antigen expressed on the cancer cells. This co-engagement induces potent NK cell activation and then tumour cell lysis without inducing systemic cytokine release, which is a dose-limiting feature of T cell engagers.
Can you share the results of Innate Pharma’s recent clinical trials?
final data from the TELLOMAK Phase II in Sezary syndrome… [showed that] in heavily pretreated patients post-mogamulizumab, with a median number of six prior therapies… the global objective response rate (ORR) was an encouraging 37.5 percent”
Regarding our clinical trials, the final data from the TELLOMAK Phase II in Sezary syndrome have been accepted for oral presentation at the 2023 annual American Society of Hematology (ASH) meeting. The recently released abstract details that in heavily pretreated patients post-mogamulizumab, with a median number of six prior therapies, the global objective response rate (ORR) was an encouraging 37.5 percent. An ORR of 46.4 percent has been also reported in the skin and 48.2 percent in the blood. A clinical benefit rate of 87.5 percent was observed. A favorable safety profile was also observed.
Additional data from the trial
Moreover, median progression free survival (mPFS) of eight months were shown, altogether confirming in a larger Phase II trial the encouraging efficacy we observed in Phase I and published in Lancet Oncology in 2019.
Beyond Sezary Syndrome, lacutamab showed also preliminary safety and efficacy in TELLOMAK on the first 21 patients having KIR3DL2-expressing Mycosis fungoides with an encouraging global response rate of 28.6 percent, reaching even 57.1 percent in the skin. We are looking forward to getting the final results by the end of the year.
[in the Phase II trial COAST] monalizumab in combination with durvalumab reduce by approximately 60 percent the risk of progression compared to durvalumab alone in patients with unresectable, Stage III NSCLC who had not progressed after concurrent chemoradiation therapy”
The monalizumab Phase III programme in the lung is based on the results of the randomised Phase II trial, called COAST, which showed that monalizumab in combination with durvalumab reduce by approximately 60 percent the risk of progression compared to durvalumab alone in patients with unresectable, Stage III NSCLC who had not progressed after concurrent chemoradiation therapy. Detailed results from COAST were published in the Journal of Clinical Oncology in 2022.
Finally, SAR’579 (SAR443579 / IPH6101) which is targeting CD123 an NKp46/CD16-based NK cell engager (NKCE). In the European Society for Medical Oncology (ESMO) clinical update for relapsed or refractory acute myeloid leukaemia (R/R AML), two of the complete responders previously reported at ASCO remained in remission after 8.8 and 12.2 months of treatment highlighting the durability of these responses.
What top three technologies have the greatest potential to transform the sector and why?
With the evolution of antibody engineering, the field is moving from monospecific antibodies to multi-specific [antibodies]”
With the evolution of antibody engineering, the field is moving from monospecific antibodies to multi-specific ones allowing interactions between receptors and/or cells that were not possible with classical antibodies and that are not naturally occurring during the development of the cancer disease, allowing to create ‘synthetic immunity’ like we are doing with our NK cells engagers by forcing the encounter with the tumour and stimulating 2 activating receptors on NK cells.
Technologies to identify and target tumour-specific antigens that most often are expressed intracellularly and presented at the cell surface through MHC-I will be important to expand the universe of druggable tumour targets.
The progress of the RNA technology and tumour specific vaccination will be also key to increase adaptive immunity against the tumour but also as it participates to the activation of the innate immunity through RNA sensing.
About the interviewee
Yannis Morel is Executive Vice President of product portfolio strategy and business development of Innate Pharma SA. He is a member of the company’s Executive Board. Having joined Innate in 2001, Yannis worked within different roles in R&D, initially as a scientist then team manager, and finally becoming responsible for research programmes. In 2007, he became in charge for business development and in 2017, also became responsible of the portfolio strategy.
He has a PhD in oncology from Aix-Marseille University, France and is an alumnus of Ecole Normale Supérieure de Paris-Saclay (previously Cachan) in physical and molecular chemistry.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.